Nanostart AG, founded in 2003 and headquartered in Frankfurt, the financial capital of Germany, is a leading nanotechnology investment company focused on accelerating the commercialization and successful growth of emerging companies with highly promising nanotechnology-based products and processes and the potential to deliver extraordinary long-term returns. Seeing nanotechnology as a radically new approach and as the greatest transformation in business and society since the industrial revolution, Nanostart identifies companies whose innovations stand to solve some of the most challenging future problems facing humankind. It targets industries such as cleantech and energy, life sciences, medicine and healthcare, and IT and electronics, typically investing directly or through a fund structure between one and ten million Euros and providing advisory support in management, commercialization and access to capital markets. Nanostart is currently invested in ten portfolio companies spanning the globe, from the research centers of Germany all the way west to Silicon Valley and east to Singapore. Through its wholly-owned subsidiary, Nanostart Asia Pte Ltd, established in 2008, and a venture capital fund, the Nanostart Singapore Early Stage Venture Fund I, launched in 2008, and a venture capital fund, the Nanostart Singapore Early Stage Venture Fund I, launched in 2009, the company is an investment partner of the Singaporean government collaborating with Singapore’s National Research Foundation, a department under the Prime Minister's Office. Nanostart’s CEO, Marco Beckmann, is a member of the Final Evaluation Panel of the Technology Enterprise Commercialisation Scheme, a government committee evaluating nanotechnology companies for government funding. With five successful IPOs of its portfolio companies to date, including NASDAQ, OTCBB and the Frankfurt Stock Exchange, as well as two trade sales of investment holdings to major corporations, most recently to global pharmaceutical leader Roche, Nanostart is likely the world's most successful venture capital provider specializing in nanotechnology.

Nanostart AG (Frankfurt: NNS)

CURRENT PRICE: €20.485
AVG DAILY VOLUME (50-DAY): 9,031
FLOAT: 1.6 million
OUTSTANDING SHARES: 5.9 million
MARKET CAPITALIZATION: €120.6 million
CURRENCY EXCHANGE RATE: USD1.00 to EUR0.75

INCOME STATEMENT HIGHLIGHTS

REVENUE: €4.7 million
EBITDA: €2.2 million
NET INCOME: €1.2 million
EPS: €0.12

All figures for twelve months ended December 31, 2009

BALANCE SHEET HIGHLIGHTS

CASH: €1.6 million
TOTAL ASSETS: €35.3 million
LONG TERM DEBT: €4.4 million
NET WORTH: €25.1 million

All figures as of December 31, 2009

RECENT COMPANY HEADLINES

August 3, 2010 — InN Nanovation AG, a portfolio company of Nanostart, announced an exclusive cooperation agreement with Ecologia Soluzione Ambientale S.p.a., one of Italy’s leading builders of wastewater treatment facilities, to use the CFM Systems® ceramic flat filter membrane technology in all construction projects. June 28, 2010 — MagForce Nanotechnologies AG (Frankfurt Stock Ex: MF6), a majority-owned subsidiary of Nanostart, announced that it has received regulatory approval for medical use of its NanoCancer® therapy throughout the European Union.

NNS PORTFOLIO COMPANIES

Germany: MagForce Nanotechnologies AG (71%), Holmenkol AG (50%), Namos GmbH (26%), InN Nanovation AG (25%)
Singapore: Curiox Biosystems Pte Ltd (19%), Biomers Pte Ltd (16%)
United States: Lumiphore Inc. (20%), BioMicro Systems, Inc. (8%), NanoGram Corporation (1%), NanoSys, Inc. (1%)

CORPORATE CONTACT INFORMATION

Nanostart AG
Goethestrasse 26-28
60313 Frankfurt, Germany
Phone: +49 61 21 93 96 00
Fax: +49 61 21 93 96 150
Web Site: www.nanostart.de
Email: info@nanostart.de

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to its accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Wall-Street Research Small Cap Conference Book, which this is a part of, or the www.WallStreetResearch.org website.

Copyright © August 2010 Alan Stone & Company LLC All Rights Reserved